Enicepatide: Roche's GLP-1 Contender

[BBA1969]

eidos said:

A further amylin analog.





Roche to present fresh obesity portfolio data at the American Diabetes Association's 2026 Scientific Sessions



Phase II data, released late-breaking, showcase the efficacy and safety of enicepatide (CT-388) and back its claim to best-in-class weight loss across a wide population of people living with...

View attachment 8693


www.roche.com

Looks like a bigger freezer is on the cards for me soon

 

[Stace_wow]

 

[JourneyToPerfection]

Any sign of this on the grey market yet? Or are we still a long way off from that?

 

[BrightCandle]

JourneyToPerfection said:

Any sign of this on the grey market yet? Or are we still a long way off from that?

No sign of it in the price sheets I follow.

 

[eidos]

JourneyToPerfection said:

Any sign of this on the grey market yet? Or are we still a long way off from that?

They've got the study running at three sites down under.

Which makes me wonder why anyone would pay for a copy when the genuine thing costs nothing.

(https://clinicaltrials.gov/study/NCT07351045)

 

[JourneyToPerfection]

eidos said:

JourneyToPerfection said:

Any sign of this on the grey market yet? Or are we still a long way off from that?

They've got the study running at three sites down under.

Which makes me wonder why anyone would pay for a copy when the genuine thing costs nothing.

(https://clinicaltrials.gov/study/NCT07351045)

Thanks, but I'd never qualify — my BMI sits in the normal range, nowhere near the obese or overweight cut-offs, and putting the weight back on isn't something I'm willing to do I still have 7-9 kg to lose, which leaves me only a handful of kilos inside the “healthy” band.

 

[eidos]

JourneyToPerfection said:

eidos said:

JourneyToPerfection said:

Any sign of this on the grey market yet? Or are we still a long way off from that?

They've got the study running at three sites down under.

Which makes me wonder why anyone would pay for a copy when the genuine thing costs nothing.

(https://clinicaltrials.gov/study/NCT07351045)

Thanks, but I'd never qualify — my BMI sits in the normal range, nowhere near the obese or overweight cut-offs, and putting the weight back on isn't something I'm willing to do I still have 7-9 kg to lose, which leaves me only a handful of kilos inside the “healthy” band.

The big players are dying off en masse.

Anyway — glad to hear it.

 

[BigDog8084]

lessthanhalf said:

In a lot of ways this looks much like tirzepatide, except that it is a biased agonist towards cAMP at both GLP-1 and GIP, whereas tirz is only biased at GLP-1. Weight loss rates come out pretty similar too, and the low dropout rate is interesting. I could not locate the actual paper, so I have no idea what the side effect rates looked like. Since weight loss had not plateaued at 48 weeks the final results are likely to be better.

Where the newer GLP drugs that are not triple agonists will all end up is very hard to know; reta is simply more effective, and the triple agonists still in development will no doubt be too. Going on the low dropout rate alone this one might have lower side effects, which would give it something to set it apart from tirz in the market. As for the injectable GLP-1 only drugs in development, I cannot see any realistic route to market success for them unless they come in cheap and land quickly, before dozens of them exist.

Genuine rivalry between manufacturers ought to push costs lower. I'll keep buying my peptides from the grey side regardless, but anyone who avoids that route might find this changes everything!